Chrisamlingmd Cv - Update 7-09

CURRICULUM VITAE Christopher L. Amling, M.D., F.A.C.S PERSONAL Birth Date: Birthplace: Spouse: Children:

December 23, 1958 Palo Alto, California Barbara L. Amling Melissa Kathleen Caroline Marie Thomas Christopher

Business Address:

Division of Urology Oregon Health & Science University Center for Health & Healing, CH10U 3303 SW Bond Avenue Portland, OR 97239

Home Address:

668 McVey Avenue, #75 Lake Oswego, OR 97034

Telephone/Fax:

(503) 346-1500/(503) 346-1501

Email Address:

[email protected]

CURRENT POSITION Professor and Chief, Division of Urology Oregon Health & Science University, Portland, Oregon

3/2009 - present

PREVIOUS POSITIONS Professor and Director, Division of Urology University of Alabama at Birmingham Endowed Chair: Anton J. Bueschen Endowed Chair in Urologic Surgery and Research, Division of Urology, University of Alabama at Birmingham Chairman, Department of Urology Naval Medical Center, San Diego, California Residency Program Director, Department of Urology Naval Medical Center, San Diego, California

ACADEMIC APPOINTMENTS

10/2005 – 2/2009

6/2006 – 2/2009

2/2004 – 7/2005 7/2002 – 7/2005

Professor, Department of Surgery, Division of Urology Oregon Health & Science University, Portland, Oregon

3/2009 – present

Professor, Department of Surgery, Division of Urology University of Alabama at Birmingham

10/2005 – 2/2009

Senior Scientist, Comprehensive Cancer Center University of Alabama at Birmingham

10/2005 – 2/2009

Assistant Professor of Surgery (Urology) Uniformed Services University of the Health Sciences

9/2000-7/2005

EDUCATION Undergraduate:

University of Oregon, Eugene, OR 1977-1981 Bachelor of Science, General Science

Medical School:

Oregon Health Sciences University, Portland, OR 1981-1985 Doctor of Medicine (Cum Laude)

Internship:

Oakland Naval Hospital, Oakland, CA 1985-1986 General Surgery internship

Aerospace Medicine:

Naval Flight Surgery Training Program Naval Aerospace Medical Institute (NAMI) Pensacola, FL 1987

Residency:

Duke University Medical Center, Durham, NC 1990-1992 Junior Resident, Department of Surgery Chairman: David C. Sabiston, M.D. Duke University Medical Center, Durham, NC 1992-1996 Resident, Department of Surgery, Division of Urology Chairman: David F. Paulson, M.D.

Fellowship:

Mayo Clinic, Rochester, MN 1996-1997 Department of Urology Urologic Oncology Fellowship Director: Horst Zincke, M.D., PhD.

MILITARY 1981 1985 1985 1986 1987 1987

Full scholarship - Navy Health Professions Scholarship Program Promoted to Lieutenant, U.S. Navy Medical Corps General Surgery Internship, Oakland Naval Hospital Staff Physician, Oakland Naval Hospital Emergency Room Winged U.S. Naval Flight Surgeon, Aerospace Medicine training, Naval Aerospace Medical Institute, Pensacola, FL (Ranked third in class) Flight Surgeon, Marine Air Group-24, Kaneohe Bay, HI 2

1988 1989 1997 1997 1998 2003 2005

1987 Senior Medical Officer and Flight Surgeon, U.S. Marine Corps Medium, Helicopter Squadron-165, Deployment to Okinawa, Japan. Awarded Naval Service and Fleet Marine Force Ribbons Flight Surgeon, VMFA-235 (U.S. Marine Corps fighter/attack squadron), Kaneohe Bay, HI Promoted to Lieutenant Commander, U.S. Navy Medical Corps Staff Urologic Oncologist, Department of Urology, Naval Medical Center, San Diego, CA Promoted to Commander, U.S. Navy Medical Corps Head, Department of Urology, USNS Mercy Hospital Ship, San Diego,CA Promoted to Captain, U.S Navy Medical Corps U.S Navy Retirement

HONORS AND AWARDS 1985 1992 1993 1998 1998 1999 1999 2000 2000 2001 2001 2002 2002 2002 2002 2003 2003 2003 2004 2004 2005 2005 2007

Cum Laude Graduate, Oregon Health Sciences University, School of Medicine Teaching Resident, Department of Surgery, Duke University Medical Center Urologic Oncology Award, Division of Urology, Duke University Medical Center Uro-Oncology Award - Best paper presented at the 46th Annual James C. Kimbrough Urologic Seminar, Williamsburg, VA Co-Author, Best Resident Paper Award (Second Place), Kimbrough Urologic Seminar, San Antonio, TX Pfizer Scholar in Urology Award, Department of Urology, Naval Medical Center, San Diego, CA Senior Author, Best Poster of Session, Western Section AUA Meeting, Palm Desert, CA Senior Author, Best Paper, Round Table Program, Western Section AUA Meeting, Palm Desert, CA Navy and Marine Corps Commendation Medial – Meritorious service as a Urologic Oncologist, Department of Urology, Naval Medical Center, San Diego, CA Senior Author, Best Resident Paper Award (First Place), Kimbrough Urologic Seminar, San Diego, CA Co-Author, Best Subspecialty Paper, San Diego Section of the American College of Surgeons Uro-Oncology Award – Best paper presented at the 49th Annual James C. Kimbrough Urologic Seminar, Seattle, WA Navy and Marine Corps Commendation Medal – Clinical research activity, Clinical Investigation Department, Naval Medical Center, San Diego, CA Staff Teaching Award, Department of Urology, Naval Medical Center, San Diego, CA Senior Author, Best Poster of Session (First Place), Western Section AUA Meeting, Kauai, HI Senior Author, Best Poster of Session (Third place), Western Section AUA Meeting, Las Vegas, NV Co-Author, First Prize, Miley B. Wesson Resident Essay Competition, Western Section AUA Meeting, Las Vegas, NV Co-Author, Outstanding Poster Presentation, Society of Urologic Oncology Annual Meeting, Bethesda, MD Senior Author, First Prize, Resident Academic Competition, San Diego Urologic Society, San Diego, CA First Prize, Best Staff Research Paper, Academic Research Competition, Clinical Investigation Department, Naval Medical Center, San Diego Senior Author, Best Resident Paper Award (Third Place), Kimbrough Urologic Seminar, Honolulu, HI Meritorious Service Medal – Navy career end award for contributions as clinician, researcher, mentor and teacher, Department of Urology, Naval Medical Center, San Diego, CA Co-Author, First Prize, Montague Boyd Essay Contest, Southeastern Section AUA Meeting, 3

2009

Orlando, FL AUA Gold Cystoscope Award, AUA Meeting, Chicago, IL

LICENSURE AND CERTIFICATION Diplomate, American Board of Urology, March 1999 Medical License, State of California, License Number G58152 (inactive) Medical License, State of Minnesota, License Number 38949 (inactive) Medical License, State of North Carolina, License Number 94-00011 (inactive) Medical License, State of Hawaii, License Number 6061(inactive) Medical License, State of Alabama, License Number 26881 Medical License, State of Oregon, License Number MD29001 Diplomate of the National Board of Medical Examiners Advanced Trauma Life Support (ATLS) Certification Basic and Advanced Cardiac Life Support (ACLS) Certification

MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS Current: Fellow, American College of Surgeons American Urologic Association Southeastern Section of the American Urologic Association (SESAUA) Local Arrangement Chairman, Southeastern Section AUA Meeting, San Diego, CA (3/08) Society of Urologic Oncology Society of University Urologists (SUU) Executive Board, Society of University Urologists (SUU) Society of Urology Chairman and Program Directors (SUCPD) Society of Government Service Urologists (SGSU) Past: Western Section, American Urologic Association (1998-2005) Alternate District Representative, Executive Board, Western Section AUA (2000-2002) District Representative, Executive Board, Western Section AUA (2003-2005) Local Arrangements Chairman, Western Section AUA Meeting, San Diego, CA, 8/2004 Vice-President, Uniformed Services Urology Research Group (2002-2003) President, Uniformed Services Urology Research Group (2004-2005) Secretary, San Diego Urologic Society (2001-2003) Vice President, San Diego Urologic Society (2003-2004) President, San Diego Urologic Society (2005)

4

NATIONAL COMMITTEES Residency Review Committee (RRC) for Urology (6/2007 – present) Program Committee, American Urological Association (5/2006 – present) Public Media Committee, American Urological Association (5/2006 – present) American Urologic Association Research Council (5/2004 - present) Chairman, Fellowship Committee, Society of Urologic Oncology (5/2007 – present) Secretary, Society of University Urologists (5/2006 – 5/2008) President-Elect, Society of University Urologists (5/2008 – present) National Comprehensive Cancer Network (NCCN) Prostate Cancer Guidelines Panel, Early Detection (10/2007 – present) ACGME Advisory Committee on Education Outcome Assessment (6/2007 – present) Prostate Subcommittee, PLCO Screening Trial (7/2007 – present)

SCIENTIFIC ACTIVITIES Editorial Boards: Journal of Urology Prostate Cancer and Prostatic Diseases Section Editor – Current Prostate Reports Journal Reviewer: Journal of Urology Urology Prostate Cancer and Prostatic Diseases European Urology Journal of the American Medical Association (JAMA) American Journal of Surgery Cancer

VISITING PROFESSORSHIPS • • • • •

• •

Mayo Clinic, Rochester, MN – January 10-11, 2002 Walter Reed Army Medical Center, Washington, DC – March 21, 2002 National Naval Medical Center, Bethesda, MD – March 22, 2002 Tripler Army Medical Center, Honolulu, HI – August 18-19, 2003 Mayo Clinic, Scottsdale, AZ – June 7-8, 2004 University of Minnesota, Minneapolis, MN – September 22-23, 2004 University of Kansas, Kansas City, KS – April 5-6, 2007

INVITED NATIONAL AND REGIONAL LECTURES • • •

•

“Use of PSA and PSA Isoforms in the Diagnosis of Prostate Cancer” - Society of Urologic Nurses Association (SUNA) National Meeting, Rochester, MN – May 1997 “Use of Complimentary Medicine in the Prevention of Prostate Cancer” – West Texas Kidney Foundation, Texas Tech University Medical Center, Lubbock, TX – September 2000 State of the Art Lecture: “Prostate Biopsy Strategies”, Kimbrough Urologic Seminar, San Diego, CA, January 2001. “Use of Adjuvant and Neoadjuvant Hormonal Therapy in the Treatment of Advanced Prostate 5

• • • • • • • • • • • • • • • • • • • • • • •

Cancer” – MEC Regional Symposium, Greensboro, NC – June 12, 2001 “Treatment of PSA Only Recurrence after Definitive Therapy for Prostate Cancer” – MEC Regional Symposium, Los Angeles, CA – September 21, 2001 “Strategies in the Treatment of Advanced Prostate Cancer” – Minnesota Urologic Society Meeting, Minneapolis, MN – January 11, 2002 “Evaluation and Treatment of PSA Only Recurrence after Radical Prostatectomy or Radiation Therapy” – ICPME Regional Symposium, Dallas, TX – February 22, 2002 “Update on the Use of Hormonal Therapy in the Treatment of Advanced Prostate Cancer” Meeting the Challenges in Abdominopelvic Malignancies in the New Mellenium, City of Hope Cancer Center, Carlsbad, CA - March 16, 2002 “Strategies in the Management of PSA Recurrence” – Washington DC Urologic Society Meeting, Washington, DC – March 21, 2002. “Multimodal Treatment of Advanced Prostate Cancer” – ICPME Regional Symposium, Houston, TX – June 21, 2002 “Evaluation and Treatment of PSA Only Recurrence after Radical Prostatectomy or Radiation Therapy” – ICPME Regional Symposium, Pasadena, CA – August 9, 2002 “Advances in the Surgical Treatment of Prostate Cancer” - Radiologic Society of San Diego Symposium, San Diego, CA - November 2002 “Update on Prostate Cancer Screening and Biopsy Techniques” – ICPME Regional Symposium, Seattle, WA – March 21, 2003 “Incorporating the ACGME Competencies Into a Urology Residency Program” – Annual ACGME Workshop – Chicago, IL - March 6, 2003 “Incorporating the ACGME Competencies Into a Urology Residency Program: The Naval Medical Center San Diego Experience” Society of University Urologists Annual Meeting, AUA Meeting, Chicago, IL – April 25, 2003 “Update on Prostate Cancer Screening and Biopsy Techniques” – ICPME Regional Symposium, Tampa, FL - May 16, 2003 “Complimentary and Alternative Medicine in Prostate Cancer” – ICPME Regional Symposium, Tampa, FL - May 16, 2003 “Complications of Advanced Prostate Cancer” – ICPME Regional Symposium, Tampa, FL - May 16, 2003 “Neoadjuvant and Adjuvant Use of Hormonal Therapy with Radical Prostatectomy” – Takeda International Advisory Board Meeting, Los Angeles, CA - June 28, 2003 “Update on Prostate Cancer Screening, Detection and Biopsy Techniques” – ICPME Regional Symposium, Kansas City, Kansas - July 18, 2003 “Incorporating the ACGME Competencies Into a Urology Residency Program: The Naval Medical Center San Diego Experience” Society of University Urologist Chairman and Program Directors Meeting, Chicago, IL – November 17, 2003 “Treatment of Advanced Prostate Cancer – A United States Perspective” – Prostate Cancer Global Opinion Leaders Workshop, Paris, France - January 29, 2004 “Update on Urologic Imaging” and “Update on Prostate Cancer Screening and Biopsy Techniques” – Loma Linda University and USC “Controversies in Urology” Meeting, Mammoth, CA – February 21, 2004 “Management Strategies for PSA Recurrence after Radical Prostatectomy or Radiation Therapy”, University of California San Francisco (UCSF) Grand Rounds – April 14, 2004 “Web-based Competency Evaluation System”, Society of University Urologists Annual Meeting, San Francisco, CA – May 7, 2004. “Current Controversies in Prostate Cancer”, Pellar Annual Endowed Lecture, Mayo Clinic, Scottsdale, AZ – June 7, 2004. “Complications of Advanced Prostate Cancer Treatment” - ICPME Regional Symposium, San Francisco, CA – June 18, 2004. 6

• • • • • • • • • • • • •

•

• •

• • • • •

“Use of Adjuvant and Neoadjuvant Hormonal Therapy in Locally Advanced Prostate Cancer”, Asian Prostate Cancer Lecture Series: Bangkok, Thailand, Manilla, Philippines and Taipei, Taiwan – July 10-18, 2004. “What’s New and in the News: Early Stage Treatment for Prostate Cancer 2004” – Perspectives in Men’s Health Regional Program, San Francisco, CA – July 23, 2004. “Complications of Advanced Prostate Cancer Treatment” - ICPME Regional Symposium, Washington, DC – July 30, 2004. “Update on Prostate Cancer Screening and Biopsy Techniques” and “Optimal Integration of Chemotherapy and Hormonal Therapy for Biochemical Recurrence”– ICPME Regional Symposium, Dearborn, MI – August 13, 2004. “Diagnosis and Treatment of Penile and Urethral Cancer” – Western Section AUA Meeting PREPC Course, San Diego, CA – August 23, 2004. “Strategies for Management of PSA Recurrence after Radical Prostatectomy or Radiation Therapy” University of Minnesota Medical Center, Minneapolis, MN – September 22, 2004 “Incorporating the ACGME Competencies Into a Residency Program: The Naval Medical Center San Diego Urology Experience” University of Minnesota Medical Center, Minneapolis, MN – September 22, 2004 “Update on the Diagnosis and Treatment of Penile and Urethral Cancer” – University of Mississippi, Jackson, MS – November, 2004. “Optimal Integration of Chemotherapy and Hormonal Therapy for Biochemical Recurrence”– ICPME Regional Symposium, Los Angeles, CA – November 5, 2004. “Strategies for Management of PSA Recurrence after Radical Prostatectomy or Radiation Therapy” - Shands Hospital, University of Florida, Gainesville, FL – January 12, 2005. “Residency Education in Military Urology Training Programs – Incorporation of the ACGME Competencies and Duty Hour Restrictions” – Kimbrough Urologic Seminar, Honolulu, HI – January 17, 2005. “Who is Most Likely to Progress?” – Issues and Controversies in Prostate Care 2005, Jamaica, W.I. - March 11, 2005. “Obesity and Prostate Cancer” – 1st Annual DukeProstateCenter (DPC) Symposium: Carolina Prostate Cancer Clinical Trials and Care Update - 2005, Duke University Medical Center, Durham, NC – April 9, 2005. “New Concepts in Prostate Cancer Screening and Prevention”, Recent Advances in the Management of Prostate Cancer, Los Angeles, CA – April 22, 2005. “Evidence­Based Use of Neoadjuvant and Adjuvant Hormonal Therapy”  ­  AUA Postgraduate  Course, San Antonio, TX ­ May 23, 2005. “Obesity and Prostate Cancer” – UAB Comprehensive Cancer Center Retreat and Research  Competition, Birmingham, AL – August 25, 2005. “Obesity and Prostate Cancer” – 2005 Urology Symposium, Santa Barbara, CA – October 21­23,  2005. “Use of Neoadjuvant and Adjuvant Hormonal Therapy with Radical Prostatectomy and  Radiotherapy” – 2005 Urology Symposium, Santa Barbara, CA – October 21­23, 2005. “Management of PSA Recurrences After Radical Prostatectomy Case Presentations” – 2005 Urology Symposium, Santa Barbara, CA – October 21-23, 2005. “Overview and Update on Penile and Urethral Cancer” – 2005 Urology Symposium, Santa Barbara, CA – October 21-23, 2005. “Clinical Applications of PSA Kinetics” – Sixth Annual Society of Urologic Oncology Meeting, Bethesda, MD – December 2-3, 2005.

7

• • •

• • • • • • • • • • • • •

• •

• • • • •

•

“Point-Counterpoint: Are the Technological Advances in the Surgical Management of Prostate Cancer Truly Advances?” – 53rd Kimbrough Urologic Seminar, Savannah, GA – January 15-20, 2006. “Clinical Applications of PSA Kinetics in Prostate Cancer” – University of Kentucky, Lexington, KY – Febraury 15, 2006. “PSA Kinetics” – TAP University, Las Vegas, NV – February 22, 2006. “Clinical Applications of PSA Kinetics” – University Associates of North Texas, Dallas, TX – April 11, 2006. “Obesity and Prostate Cancer” – Advances in Uro-Oncology: Eine Festschrift for Horst Zincke, MD, PhD, Rochester, MN – April 29, 2006. “Hormonal Therapy and Prostate Cancer: New Uses for an Old Treatment” – AUA Postgraduate Course, Atlanta, GA – May 24, 2006. “Treatments and Risk Factors for Prostate Cancer” – Conference on Cancer Survivorship Issues in the African-American Community, Birmingham, AL – June 6, 2006. “Update on Robotic Prostatectomy: Is it Better Than Open Prostatectomy?” – 2006 Prostate Cancer Review: Redefining Patient Care”, Tampa, FL – June 16, 2006. “Defining High-Risk Disease: Risk Stratification and PSA Kinetics” – 2006 Prostate Cancer Review: Redefining Patient Care”, Tampa, FL – June 16, 2006. “Clinical Applications of PSA Kinetics in Prostate Cancer” – Urology Seminar, Destin, FL – July 13-16, 2006. “Upate on Robotic Prostatectomy for Prostate Cancer” – University of Alabama at Birmingham, Department of Surgery Grand Rounds, Birmingham, AL – August 17, 2006. “Update on Robotic Prostatectomy: Is it Better Than Open Prostatectomy?” – 2006 Prostate Cancer Review: Redefining Patient Care, Washington, DC – September 15, 2006. Defining High-Risk Disease: Risk Stratification and PSA Kinetics” – 2006 Prostate Cancer Review: Redefining Patient Care, Washington, DC – September 15, 2006. “Robotics, Laparoscopic and Open Prostatectomy Options” – Annual Multidisciplinary Approach to the Management of Prostate and GU Cancer Conference, Dallas, TX – September 29-October, 1 2006. “Update on Robotic Prostatectomy: Is it Better Than Open Prostatectomy?” – 2006 Prostate Cancer Review: Redefining Patient Care”, Chicago, IL – October 27, 2006. “Defining High-Risk Disease: Risk Stratification and PSA Kinetics” – 2006 Prostate Cancer Review: Redefining Patient Care”, Chicago, IL – October 27, 2006. “Robotic Prostatectomy” – 4th Annual Georgia Urological Association Spring Meeting & Urology Resident Research Expo, Savannah, GA – February 16-18, 2007. “Hormonal Therapy and Prostate Cancer: Evidence Based Approaches in 2007.” – AUA Postgraduate Course, Anaheim, CA - May 2007. “Chemoprevention / Risk Factors for Prostate Cancer” – The Minnesota Urological Society Annual Spring Seminar, St Paul, MN – May 11-12, 2007. “New and Emerging Technologies in Prostate Cancer Prevention, Diagnosis and Treatment” –  Prostate Cancer Summit 2007 Call to Action, Birmingham, AL – June 2007. “Point-Counterpoint: Is Robotic Prostatectomy Really Better than Open Prostatectomy?” –  Urology Seminar, Destin, FL – August 9­12, 2007. “The Role of Radical Prostatectomy in High Risk Prostate Cancer” – Urology Seminar, Destin,  FL – August 9­12, 2007. “Core Competencies” University of Alabama School of Medicine Surgery Grand Rounds,  Birmingham, AL – August 23, 2007. “The Role of Obesity in Urology” – AUA Northeastern Section Meeting, Rochester, NY – September 6-7, 2007. 8

• •

“Current Challenges in Urology Residency Training” – AUA Northeastern Section Meeting, Rochester, NY – September 6-7, 2007. “Hormonal Therapy and Prostate Cancer: Evidence Based Approaches in 2008.” – AUA Postgraduate Course, Orlando, FL - May 2008.

RESEARCH SUPPORT •

•

•

•

•

•

• •

•

Current: TNG-CL005, Tengion, Inc. – A Multicenter Study to Obtain Full Thickness Bladder Tissue Specimens from Subjects Undergoing Cystectomy Role: PI 1/1/2007-7/31/2009 $25,494 Purpose: To obtain full-thickness bladder wall tissue at the time of cystectomy for use in development of bladder tissue constructs UAHSF Endowment Grant – UAB Men’s Contienence Center Role: CI 3/1/2008-2/28/2010 $164,680 Purpose: To follow a chort of men undergoing radical prostatectomy and collect followup data on health status and quality-of-life for one year after surgery NCI N01-CN-75022 – Prostate, Lung, Colo-rectal and Ovarian (PLCO) Cancer Screening Trial Role: CI 9/1/2007-9/29/2009 $9,372 Purpose: Evaluate effectiveness of screening for prostate cancer; includes a biorepository (blood samples) and accompanying data collection on risk factors VA01162 Cooperative Studies Program – Chemotherapy after Prostatectomy for High Risk Prostate Cancer: A Phase III Randomized Study Role: CI 1/1/2008-12/31/2008 Purpose: Investigate effectiveness of adjuvant chemotherapy to decrease recurrence rate after radical prostatectomy for high risk prostate cancer patients 2008 GSR-DG - Geriatrics Education for Specialty Residents Dissemination Grant Role: CI 7/1/2008-6/30/2009 $25,000 Pupose: Improvement of geriatric education among urology residents by development and implementation of curricula and expansion of research focusing on the geriatric population UAB X030820007 – Protocol for Obtaining Solid Tissues, Fluids, and Information for Genitourinary Cancer Research Role: PI 1/1/2006-12/31/2009 Pupose: Develop tissue and body fluid repository for use in urologic cancer research Pending: UAB 0516 (NCI -University of Wisconsin Consortium) – Phase II Study of Isoflavone G-2535 (Genistein) in Patients with Baldder Cancer Role: CI UAB 0810 (NCI -University of Wisconsin Consortium) – Phase II Randomized PlaceboControlled Trial of Polyphenono-E to Evaluate Baldder Tissue Levels of EGCG Role: CI Past: DOD Center for Prostate Disease Research Grant . – Military Multicenter Prostate Cancer Database Investigating Patterns of Care, Outcomes and Prognostic Factors Role: Site (NMCSD) PI 9

•

•

• • •

DOD-Armed Forces Institute of Pathology Grant – A Uniformed Services Comprehensive Database and Tissue Repository for the Study of Epidemiology, Detection, Natural History and New Management Strategies for Prostate Cancer Role: Site (NMCSD) PI Astra-Zeneca Pharmaceuticals – A Randomized Double-Blind Comparitive Trial of Bicalutamide (Casodex) 150 mg Monotherapy versus Placebo in Patients with a Rising PSA after Radical Prostatectomy Role: Site (NMCSD) PI Sidney Kimmel Cancer Center (SKCC) Grant – Tissue Collection for Investigation of Vascular Markers in Urologic Malignancies Role: Site (NMCSD) PI Ortho-McNeil Pharmaceuticals – A Multicenter, Double-Blind Study to Compare the Safety and Efficacy of Levofloxacin to Ciprofloxacin in the Treatment of Chronic Prostatitis Role: Site (NMCSD) PI American Medical Systems – Evaluation of the Safety and Tolerability of Transurethral Dehydrated Alcohol Injection for the Treatment of Benign Prostatic Hyperplasia Role: Site (NMCSD) PI

PEER-REVIEWED PUBLICATIONS 1. 2. 3. 4. 5. 6.

7. 8. 9. 10.

Amling, C.L., Thrasher, J.B., Frazier, H.A., Dodge, R.K., Robertson, J.E. and Paulson D.F.: Radical cystectomy for stages Ta. Tis and T1 transitional cell carcinoma of the bladder. J. Urol., 151:31-36, 1994. Amling, C.L., O’Hara, S.M., Wiener, J.S., Schaeffer, C.S. and King, L.R.: Renal ultrasound changes following pyeloplasty in children with UPJ obstruction: Long term outcome in 47 renal units. J.Urol., 156:2020-2024, 1996. Lo, J., Kerns, B.J., Amling, C.L., Robertson, C.N. and Layfield, L.J.: Correlation of DNA ploidy and histologic diagnosis for prostate core needle biopsies: Is DNA ploidy more sensitive than histology for the diagnosis of carcinoma in small specimens? J Surg Oncol 63(1):41-45, 1996. Amling, C.L., Blute, M.L., Lerner, S.E., Bergstralh, E.J., Bostwick, D.G. and Zincke, H.: Influence of PSA testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice. Mayo Clin Proc 73:401-406, 1998. Amling, C.L., Blute, M.L., Bergstralh, E.J., Slezak, J.M., Martin, S.K. and Zincke, H.: Preoperative androgen deprivation therapy for clinical stage T3 prostate cancer. Semin Urol Oncol 15(4):222-229, 1997. Amling, C.L., Leibovich, B.C., Lerner, S.E., Bergstralh, E.J., Blute, M.L., Myers, R.P. and  Zincke, H.:  Primary surgical therapy for clinical stage T3 adenocarcinoma of the prostate.  Semin Urol Oncol 15(4):215­221, 1997. Blute, M.L., Bostwick D.G., Bergstralh, E.J., Martin, S. K., Amling, C.L. and Zincke, H.: Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy. Urology 50:733-739, 1997. Amling, C.L., Lerner, S.E., Martin, S.K., Slezak, J.M., Blute, M.L. and Zincke, H.: DNA ploidy and serum PSA levels predict outome following salvage prostatectomy for radiation refractory prostate cancer. J Urol 161:857-863, 1999. Lerner, S.E., Amling, C.L., Kaynan, A.M., Blute, M.L. and Zincke, H.: The role of salvage surgery in radio-recurrent/resistant carcinoma of the prostate. AUA Update, Vol 28 (Lesson 8), 1999. Borboroglu, P.G., Roberts, J.L. and Amling, C.L.: Late pelvic recurrence of nonseminomatous testicular carcinoma after negative retroperitoneal lymph node dissection. Urology 54:923-924, 1999. 10

11. 12. 13. 14. 15.

16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26.

27. 28.

29.

Borboroglu, P.G., Comer, S.W., Riffenburgh, R.H. and Amling, C.L.: Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies. J Urol 163:158-162, 2000. Borboroglu, P.G., Sands, J.P., Roberts, J.L. and Amling, C.L.: Risk factors for vesicourethral anastomotic stricturs after radical prostatectomy. Urology 56:96-100, 2000. Amling, C.L., Seay, T,M., Blute, M.L., Bergstralh, E.J. and Zincke, H.: Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: Continued risk of biochemical failure after five years. J Urol 164:101-105, 2000. Blute, M.L., Amling, C.L., Bryant, S.C. and Zincke, H.: Mangement and extended outcome of patients with synchronous bilateral solid renal neoplasms in the absence of Von Hippel-Lindau disease. Mayo Clin Proc 75(10):1020-1026, 2000. Borboroglu, P.G. and Amling, C.L.: Correlation of prostate sextant biopsy location to sites of positive surgical margins in radical prostatectomy specimens. Eur Urol 39:638-644, 2001. Tarman, G.J., Kane, C.J., Moul, J.W., Thrasher, J.B., Foley, J., Riffenburgh, R.H. and Amling, C.L.: Impact of socioeconomic status and race on clinical parameters of patients undergoing radical prostatectomy in an equal access health care system. Urology 56:1016-1020, 2000. Ward, J.F., Sands, J.P., Nowacki, M.R. and Amling, C.L.: Malignant cells in prostate washings predicts biochemical progression after radical prostatectomy. J Urol 165:469-473, 2001. Amling, C.L., Blute, M.L., Bergstralh, E.J., Slezak, J. and Zincke, H.: Defining biochemical progression after radical prostatectomy: What is the most appropriate PSA cut-point? J Urol 165:1146-51, 2001. Gray, C.L., Powell, C.R. and Amling, C.L.: Outcomes for surgical management of scrotal pain in patients with identifiable intrascrotal lesions. Eur Urol 39:455-459, 2001. Borboroglu, P.G., Sur, R.L., Roberts, J.L. and Amling, C.L.: Repeat biopsy strategy in patients with atypical small acinar proliferation or high grade prostatic intraepithelial neoplasia on initial prostate biopsy. J Urol 166:866-870, 2001. Amling, C.L., Kane, C.J., Ward, J.F., Roberts, J.L., Lance, R.S., Friedrichs, P.A. and Moul, J.W.: Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology 58:723-728, 2001. Borboroglu. P.G., Amling, C.L., Bishoff, J.T., Monga, M., Schenkman, N.S. and Kane, C.J.: Ureteral stenting after ureteroscopy for distal ureteral calculi: Multi-institutional prospective randomized study assessing pain, outcomes and complications. J Urol 166:1651-1657, 2001. Johnstone, P.A.S., McFarland, J.T., Riffenburgh, R.H. and Amling, C.L.: Efficacy of digital rectal examination after radiotherapy for prostate cancer. J Urol 166:1684-1687, 2001. Amling, C.L.: Diagnosis and management of superficial bladder cancer. Curr Probl Cancer 25(4):217-280, 2001. Gray, C.L., Amling, C.L., Polston, G.R., Powell, C.R. and Kane, C.J.: Intraoperative cell salvage in radical retropubic prostatectomy. Urology 58:740-745, 2001. Moul, J.W., Wu, H., Sun, L., Mcleod, D.G., Amling, C.L., Lance, R., Kusuda, L., Donahue, T., Foley, J., Chung, A., Sexton, W., Soderdahl, D.: Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen (PSA): An overview of the DOD Center for Prostate Disease Research (CPDR) National Database. Surgery 132:213-9, 2002. Freedland SJ, Amling CL, Dorey F, Kane CJ, Presti JC Jr., Terris MK, and Aronson WJ. Race as an outcome predictor following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Urol 60: 670-674, 2002. Johnstone PAS, Kane CJ, Sun L, Wu H, Moul JW, McLeod DG, Martin DD, Kusuda L, Lance R, Douglas R, Donahue T, Beat MG, Foley J, Baldwin D, Soderdahl D, Do J, Amling CL: The effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: Radiation oncology report of the DOD Center for Prostate Disease Research. Radiology 225:420-6, 2002. Gray-Sears, C.L., Ward, J.F., Sears, S.T., Puckett, M.L. Kane, C.J. and Amling, C.L.: Prospective 11

30.

31. 32. 33.

34. 35. 36.

37. 38. 39.

40.

41.

42.

43.

comparison of CT and IVP in the initial evaluation of asymptomatic microhematuria. J Urol 168:2457-60, 2002. Desai A., Wu H., Sun L, Sesterhenn I.A., Mostofi F.K., McLeod D., Amling C., Kusuda L.,  Lance R., Herring J., Foley J., Baldwin D., Bishoff JT., Soderdahl D., Moul J.W. Complete  embedding and close step­sectioning of radical prostatectomy specimens both increase detection  of extra­prostatic extension, and correlate with increased disease­free survival by stage of prostate  cancer patients. Prostate Cancer Prostatic Dis. 5:212­18, 2002. Johnstone, P.A.S., Booth, R., Riffenburgh, R.H., Amling, C.L., Kane, C.J. and Moul, J.W.: Initiation of salvage therapy for prostate cancer. Prostatic Cancer Prostatic Dis 5:136-43, 2002. Freedland SJ, Kane CJ, Presti JC Jr., Terris MK, Amling CL, Dorey F, and Aronson WJ. Comparison of preoperative PSA density and PSA for predicting recurrence after radical prostatectomy: Results from the SEARCH database. J Urol 169:969-73, 2003. Johnstone PAS, Bloom TL, Niemtzow RC, Crain DS, Riffenburgh RH, Amling CL: A  prospecitive, randomized pilot trial of acupuncture of the kidney­bladder distinct meridian for  lower urinary tract symptoms. J Urol 169:1037­9, 2003. Bloom TL, Gray­Sears CL, Williams TR, Linfesty RL, Amling CL: Multilocular cystic renal cell  carcinoma with osseous metaplasia in a 25­year old woman. Urology 61:462, 2003. Ward JW, Amling CL, McKusick MA: The use of percutaneous transcatheter embolization in urology. AUA Update, Vol 22 (Lesson 39 ), 2003. Johnstone, P.A.S., Riffenburgh R.H., Kane, C.J., Sun, L., Moul, J.W., McLeod, D.G., Martin, D.D., Kusuda, L., Lance, R.L., Donahue, T., Foley, J., Soderdahl, D., Amling, C.L.: The effect of age on biochemical disease-free outcome in patients with T1-3 prostate cancer treated with definitive radiation therapy in an equal-access health care system: A radiation oncology report of the DOD Center for Prostate Disease Research. Int J Radiat Oncol Biol Phys 15;55:964-9, 2003. Kane, C.J., Amling, C.L., Johnstone, P.A.S., Pak, N., Lance, R.S., Thrasher, J.B., Foley, J.P., Riffenburgh, R. and Moul, J.W.: Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 61:607-11, 2003. Riffenburgh RH, Amling CL: Use of early PSA velocity to predict eventual abnormal values in men at risk for prostate cancer. Prostate Cancer Prostatic Dis. 6:39-44, 2003. Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr., Amling CL, Dorey F, and Terris MK. Time  trends in biochemical recurrence following radical prostatectomy: results of the SEARCH  database. Urology 61:736­41, 2003. Freedland SJ, Aronson WJ, Csathy GS, Kane CJ, Amling CL, Presti JC Jr., Dorey F, and Terris MK: Comparison of percent of total prostate needle biopsy tissue with cancer to percent of cores with cancer for predicting PSA recurrence following radical prostatectomy: results from the SEARCH database. Urology 61:742-7, 2003. Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling CL, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Donahue T: Pretreatment total testosterone level predicts pathologic stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 169:1670-5, 2003. Freedland SJ, Aronson WJ, Presti JC Jr., Terris MK, Kane CJ, Dorey F, Amling CL: Improved  clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2  prostate cancer: results from the SEARCH database. J Urol 169:2129, 2003. Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, and Presti JC Jr. Percent  of prostate needle biopsy cores with cancer is a significant independent predictor of PSA 

12

44.

45. 46. 47.

48.

49.

50.

51.

52.

53.

54.

55. 56. 57.

recurrence following radical prostatectomy: Results from the SEARCH Database. J Urol  169:2136, 2003. Freedland SJ, Aronson WJ, Presti JC Jr., Kane CJ, Terris MK, Elashoff D, and Amling CL.  Should a positive surgical margin following radical prostatectomy be pathological stage T2 or  T3? Results from the SEARCH Database.  J Urol 169:2142, 2003. Crain DS, Roberts JL, Amling CL: Practice patterns in vasectomy reversal surgery: A  questionnaire study among practicing urologists. J Urol 171:311-5, 2004 Crain DS, Amling CL Kane CJ: Palliative TURP for bladder outlet obstruction in patients with  locally advanced prostate cancer. J Urol 171:668­71, 2004. Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, Sexton WJ, Soderdahl DW, DonahueTF, Foley JP, Chung AK, McLeod DG: Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Onc 22:439-45, 2004 Altamar HO, Middleton GW, Capozza TA, Auge BK, Amling CL: Profound anemia from duodenal invasion of metastatic testicular seminoma. J Urol 171:344-5, 2004. Freedland SJ, Aronson WJ, Kane CJ, Presti JC, Amling CL, Elashoff D, Terris MK: Impact of obesity on biochemical control following radical prostatectomy for clinically localized prostate cancer. J Clin Onc 22:446-53, 2004. Carter CA, Donahue T, Sun L, Wu H, McLeod DG, Amling CL, Lance R, Foley J, Sexton W,  Kusuda L, Chung A, Soderdahl D, Jackman S, Moul JW: Temporarily deferred therapy (watchful  waiting) for men younger than 70 years and with low­risk localized prostate cancer in the  prostate­specific antigen era. J Clin Oncol 21(21):4001­8, 2003. Freedland SJ, Amling CL, Terris MK, Presti JC Jr, Aronson WJ, Elashoff D, and Kane CJ. Is there a difference in outcome after radical prostatectomy between patients with biopsy Gleason sums 4, 5, and 6? Results from the SEARCH Database. Prostate Cancer Prostatic Dis. 2003;6(3):261265. Moul J, Sun L, McLeod D, Amling C, Lance R, Kusuda L, Donahue T, Foley J, Chung A, Sexton W, Soderdahl D, Wu H. A retrospective review on 542 cases in the past decade on associations between bone metastasis and PSA level, bone pain, and race in prostate cancer patients. Oncology 17(4 Suppl):47-78, 2003 Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, Presti JC: The percentage of prostate needle biopsy cores with cancer from the more involved side of the biopsy as a predictor of PSA recurrence following radical prostatectomy. Cancer 98(11):2344-50, 2003. Moul JW, Sun L, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Donahue T. Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the department of defense (DOD) Center for Prostate Disease Research (CPDR) national database. Urol Oncol. 2003; 21(6):447-55. Freedland SJ, Presti JC Jr., Kane CJ, Aronson WJ, Terris MK, Dorey F, and Amling CL. Do younger men have better biochemical outcomes following radical prostatectomy? Urology 63:51822, 2004. Moul JW, Sun L, Wu H, McLeod DG, Amling C, Donahue T, Kusuda L, Sexton W, O’Reilly K, Hernandez J, Chung A, Soderdahl D. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 171:1141-1147, 2004 Wu H, Sun L, Moul JW, McLeod DG, Amling C, Lance R, Kusuda L, Donahue T Foley J, Chung A, Sexton W, Soderdahl D. Watchful waiting and factors predictive of secondary treatment of localized prostate cancer. J Urol 171:1111-1116, 2004. 13

58. 59.

60.

61.

62.

63.

64.

65. 66. 67.

68. 69.

70. 71. 72.

73. 74. 75.

Sur RL, Borboroglu PG, Roberts JL, Amling, CL. A prospective randomized comparison of extensive prostate biopsy to standard biopsy with assessment of diagnostic yield, biopsy pain and morbidity. Prostate Cancer Prostatic Dis (Epub ahead of print) 2004. Freedland SJ, Aronson WJ, Presti JC Jr. , Amling CL, Terris MK, Trock B, Kane CJ.  Predictors  of PSA progression among men with seminal vesicle invasion at the time of radical  prostatectomy.  Cancer 100:1633­8, 2004. Crum NF, Spencer CR, Amling CL: Prostate cancer among human immunodeficiency virus  (HIV) –infected men. Cancer 101:294­9, 2004. Freedland SJ, Terris MK, Csathy GS, Kane CJ, Amling CL Presti JC, Dorey F, Aronson WJ: Pre­ operative model for predicting PSA recurrence after radical prostatectomy using percent of  biopsy tissue with cancer, biopsy Gleason grade, and serum PSA. J Urol 171: 2215, 2004. Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Presti JC Jr. , Trock B, Amling CL.  Biochemical outcome following radical prostatectomy among men with normal pre­operative  serum PSA values.  Cancer 101:748­53, 2004. Crain DS, Spencer CR, Favata MA, Amling CL: Transureteral iced saline to obtain renal hypothermia: Potential for application in laparoscopic partial nephrectomy. JSLS 8:217-222, 2004. Freedland SJ, Terris MK, Presti JC Jr. , Amling CL, Kane CJ, Trock B, and Aronson WJ.  Obesity  and biochemical outcome following radical prostatectomy for pathologically organ­confined  disease with negative surgical margins.  J. Urol 172:520­4, 2004. Amling CL: Biochemical failure: role for early hormonal therapy. BJU Int 94 Suppl 3:9-10, 2004. Amling CL: Advanced prostate cancer treatment guidelines: a United States perspective. BJU Int 94 Suppl 3:7-8, 2004 Amling CL: The association between obesity and the progression of prostate and renal cell  carcinoma. Urol Oncol 22(6):478­84, 2004. Amling, CL: Case studies in prostate cancer. BJU Int 94 Suppl 3:18-9, 2004. Langenstroer P, Poulton T, Kramer B, Cutting B, Amling CL, Lance RS, Thrasher JB. Multiinstitutional evaluation of depo-provera for the treatment of hot flashes associated with androgen ablation for prostate cancer. J Urol 174: 642-645, 2005. Gaylis FD, Ignatoff JM, Amling CL, Tutrone RF, Cosgrove DJ: Prostate cancer in men using testosterone supplementation. J Urol 174: 534-538, 2005. Amling CL: Relationship between obesity and prostate cancer. Curr Opin Urol 15(3): 167-171, 2005. Langenstroer P, Kramer B, Cutting B, Amling C, Poultan T, Lance R, Thrasher JB: Parenteral medroxyprogesterone for the management of luteinizing hormone releasing hormone induced hot flashes in men with advanced prostate cancer. J Urol 174: 642-645, 2005. Crum NF, Furtek KJ, Olson PE, Amling CL, Wallace MR: A review of hypogonadism and erectile dysfunction among HIV-infected men during the pre- and post-HAART eras: Diagnosis, pathogenesis, and management. AIDS Patient Care STDS 19: 655-71, 2005. Freedland SJ, Isaacs WB, Platz EA, Terris MK, Aronson WJ, Amling CL, Presti JC Jr, Kane CJ: Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol: 23: 7546-54, 2005. Freedland SJ, Aronson WJ, Trock B, Cohen P, Kane CJ, Amling CL, Presti JC Jr, Terris MK; Shared Equal Access Regional Cancer Hospital Database Study Group: Radical differences in prognostic value of adult height for biochemical progression following radical prostatectomy. Clin Cancer Res 11: 7735-42, 2005. 14

76. 77. 78. 79.

80. 81. 82. 83. 84. 85. 86. 87. 88. 89.

90. 91. 92. 93. 94.

Freedland SJ, Platz EA, Presti JC Jr, Aronson WJ, Amling CL, Kane CJ, Terris MK: Obesity, serum prostate specific antigen and prostate size: Implications for prostate cancer detection. J Urol 175: 500-4, 2006. Freeland SJ, Kane CJ, Amling CL, Aronson WJ, Presti JC Jr, Terris MK, SEARCH Database Study Group: Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer. J Urol 175: 1298-302, 2006. Amling CL: Biochemical recurrence after localized treatment. Urol Clin North AM 33: 147-59, 2006. Bastian PJ, Gonzalgo ML, Aronson WJ, Terris MK, Kane CJ, Amling CL, Presti JC Jr, Mangold LA, Humphreys E, Epstein JI, Partin AW, Freedland SJ: Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer 107: 1265-72, 2006. Amling CL: Prostate-specific antigen and detection of prostate cancer: What have we learned and what should we recommend for screening? Curr Treat Options Oncol 7: 337-45, 2006. Amling CL: Dilemmas in management of the small renal mass. Curr Opin Urol 16: 315-6, 2006. Cooperberg MR, Freedland SJ, Pasta DJ, Elkin EP, Presti JC Jr, Amling CL, Terris MK, Aronson WJ, Kane CJ, Carroll PR: Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer 107: 2384-91, 2006. Morey AF, Evans LA, McDonough RC, Park AM, Sexton WJ, Basler JW, Santucci RA, Amling CL, O’Reilly KJ: Evaluation of mechanical bowel preparation methods in urinary diversion surgery. Can J Urol 13: 3250-4, 2006. Fitzsimons NJ, Presti JC Jr, Kane CJ, Terris MK, Aronson WJ, Amling CL, Freedland SJ: Is biopsy Gleason score independently associated with biochemical progression following radical prostatectomy after adjusting for pathological Gleason score? J Urol 176: 2453-8, 2006. Kane CJ, Presti JC Jr, Amling CL, Aronson WJ, Terris MK, Fredland SJ, SEARCH Database study group: Changing nature of high risk patients undergoing radical prostatectomy. J Urol 177: 113-7, 2007. Crum-Cianflone NJ, Bavaron M, Hale B, Amling CL, Truett A, Brandt C, Pope B, Furtek K, Medina S, Wallace MR: Erectile dysfunction and hypogonadism among men with HIV. AIDS Patient Care STDS 21: 9-19, 2007. Plante MK, Marks LS, Anderson R, Amling CL, Rukstalis D, Badlani G, Getlin L, Vang E: Phase I/II examination of transurethral ethanol ablation of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol 177: 1030-5, 2007. Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Terris MK, Presti JC Jr, SEARCH Database Study Group: Upgrading and downgrading of prostate needle biopsy specimens: risk factors and clinical implications. Urology 69: 495-9, 2007. Strang AM, Lockhart ME, Kenney PJ, Amling CL, Urban DA, El-Galley R, Burns JR, Colli JL, Hammontree LN, Kolettis PN: Computerized tomographic angiography for renal donor evaluation leads to a higher exclusion rate. J Urol 177: 1826-9, 2007. King CR, Freedland SJ, Terri MK, Aronson WJ, Kane CJ, Amling CL, Presti JC Jr: Optimal timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from SEARCH. Urology 69: 732-7, 2007. King CR, Freedland SJ, Terris MK, Kane CJ, Amling CL, Aronson WJ, Presti JC Jr: Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: A report from the SEARCH database. Urology 69: 921-6, 2007. Mavropoulos JC, Partin AW, Amling CL, Terris MK, Kane CJ, Aronson WJ, Presti JC Jr, Mangold LA, Freedland SJ: Do racial differences in prostate size explain higher serum prostatespecific antigen concentrations among black men? Urology 69: 1138-42, 2007. Sajadi KP, Terris MK, Hamilton RK, Cullen J, Amling CL, Kane CJ, Presti JC Jr, Aronson WJ, Freedland SJ: Body mass index, prostate weight and transrectal ultrasound prostate volume accuracy. J Urol 178: 990-5, 2007. Scales CD Jr., Presti JC Jr, Kane CJ, Terris MK, Aronson WJ, Amling CL, Freedland SJ, for the SEARCH Database Study Group: Predicting unilateral prostate cancer based on biopsy features: 15

95.

96.

97. 98. 99.

100.

101. 102.

103. 104. 105.

106. 107.

108. 109.

Implications for focal ablative therapy-Results from the SEARCH Database. J Urol 178: 124952, 2007. Kang DE, Fitzsimons NJ, Presti JC Jr, Kane CJ, Terris MK, Aronson WJ, Amling CL, Freedland SJ; SEARCH Database Study Group: Risk stratification of men with Gleason score 7 to 10 tumors by primary and secondary Gleason score: Results from the SEARCH Database. Urology 70(2): 277-82, 2007. Banez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriquez C, Wang Y, Terri MK, Aronson WJ, Presti JC Jr, Kane CJ, Amling CL, Moul JW, Freedland SJ: Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 298 (19): 2275-80, 2007. Hamilton RJ, Aronson WJ, Presti JC Jr, Terris MK, Kane CJ, Amling CL, Freedland SJ: Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: Results from the SEARCH Database. Cancer 110(10): 2153-4, 2007. Buschemeyer WJ 3rd, Hamilton RJ, Aronson WJ, Presti JC Jr, Terris MK, Kane CJ, Amling CL, Freedland SJ: Is a positive bladder neck margin truly a T4 lesion in the prostate specific antigen era? Results from the SEARCH Database. J Urol 179: 124-9, 2008. Heath EI, Kattan MW, Powell IJ, Sakr W, Brand TC, Rybicki BA, Thompson IM, Aronson WJ, Terris MK, Kane CJ, Presti JC Jr, Amling CL, Freedland SJ: The effect of race/ethnicity on the accuracy of the 2001 Partin Tables for predicting pathologic stage of localized prostate cancer. Urology 71(1):151-5, 2008. Turley RS, Hamilton RJ, Terris MK, Kane CJ, Aronson WJ, Presti JC Jr, Amling CL, Freedland SJ; SEARCH Database Study Group: Small transrectal ultrasound volume predicts clinically significant Gleason score upgrading after radical prostatectomy: Results from the SEARCH database. J Urol 179(2): 523-7, 2008. Sengupta S, Amling C, D’Amico AV, Blute ML: Prostate specific antigen kinetics in the management of prostate cancer. J Urol 179(3):821-6, 2008. Strang AM, Lockhart ME, Amling CL, Kolettis PN, Burns JR: Living renal donor allograft lithiasis: A review of stone related morbidity in donors and recipients. J Urol 179(3):832-6, 2008. Colli JL, Amling CL: Exploring causes for declining prostate cancer mortality rates in the United States. Urol Oncol. 2008 Jan 11. [Epub ahead of print] Colli JL, Amling CL: Prostate cancer mortality rates compared to urologist population densities and prostate-specific antigen screening levels on a state-by-state basis in the United States of America. Prostate Cancer Prostatic Dis. 2008 Feb 12. [Epub ahead of print] Heath EI, Kattan MW, Powell IJ, Sakr W, Brand TC, Rybicki BA, Thompson IM, Aronson WJ, Terris MK, Kane CJ, Presti JC Jr, Amling CL, Freedland SJ: Small transrectal ultrasound volume predicts clinically significant Gleason score upgrading after radical prostatectomy: results from the SEARCH database. J Urol. 2008 179(2):523-7. Colli JL, Amling CL: High cholesterol levels are associated with reduced prostate cancer mortality rates during periods of high but not low statin use in the United States. Urol Oncol. 2008 Feb 1. [Epub ahead of print] Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, Kusuda L, Sexton W, O'Reilly K, Hernandez J, Chung A, Soderdahl D: Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol. 2008, 179(5 Suppl):S53-9. Cox J, Amling CL: Current decision-making in prostate cancer therapy. Curr Opin Urol. 2008, 18(3):275-8. Hamilton RJ, Aronson WJ, Terris MK, Kane CJ, Presti JC Jr, Amling CL, Freedland SJ: Limitations of prostate specific antigen doubling time following biochemical recurrence after 16

110.

111. 112.

113.

114. 115.

116.

117.

118.

radical prostatectomy: results from the SEARCH database. J Urol. 2008;179(5):1785-9; discussion 1789-90. Epub 2008 Mar 17. Jayachandran J, Bañez LL, Levy DE, Aronson WJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, Freedland SJ; SEARCH Database Study Group: Risk stratification for biochemical recurrence in men with positive surgical margins or extracapsular disease after radical prostatectomy: results from the SEARCH database. J Urol. 2008;179(5):1791-6; discussion 1796. Epub 2008 Mar 17. Nelles JL, Freedland SJ, Presti JC Jr, Terris MK, Aronson WJ, Amling CL, Kane CJ: Impact of nerve sparing on surgical margins and biochemical recurrence: results from the SEARCH database. Prostate Cancer Prostatic Dis. 2008 Jul 15. Epub ahead of print. Freedland SJ, Sun L, Kane CJ, Presti JC Jr, Terris MK, Amling CL, Moul JW, Aronson WJ: Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigenbased prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Cancer databases. Brit J Urol Internat 2008 Sept; 102(8):969-74, Epub 2008 August 7. SEARCH Database Study Group, Jayachandran J, Aronson WJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, Freedland SJ: Obesity and positive surgical margins by anatomic location after radical prostatectomy: results from the Shared Equal Access Recional Cancer Hospital database. Brit J Urol Internat 2008 Sep; 102(8):964-8. Epub 2008 July 7. Colli JL, Busby JE, Amling CL: Renal cell carcinoma rates compared with health status and behavior in the United States. Urology 2009 Feb; 73(2):431-6. Epub 2008 August 13. Turley RS, Terris MK, Kane CJ, Aronson WJ, Presti JC Jr, Amling CL, Freedland SJ; SEARCH Database Study Group. The association between prostate size and Gleason score upgrading depends on the number of biopsy cores obtained: results from the Shared Equal Access Regional Cancer Hospital Database. Brit J. Urol Internat 2008 Nov; 102(9):1074-9. Epub 2008 Sep 3. Teeter AE, Banez LL, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ, SEARCH Database Group: What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group. J Urol 2008 Nov; 180(5):1980-4; discussion 1985. Epub 2008 Sep 17. Poliakov A, Spilman M, Dokland T, Amling CL, Mobley JA: Structural heterogeneity and protein composition of exosome-like vesicles (prostasomes) in human serum. Prostate. 2009 Feb 1; 69(2):159-67. Schroeck FR, Aronson WJ, Presti JC Jr, Terris MK, Kane CJ, Amling CL, Freedland SJ: Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone? Brit J Urol Internat 2009 Mar; 103(5):603-8. Epub 2008 Nov 18. 119. Shah SE, Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr, Amling CL, Terris MK: Exposure to Agent Orange is a significant predictor of prostate-specific antigen (PSA)-based recurrence and a rapid PSA doubling time after radical prostatectomy. Brit J Urol Internat 2009 Mar 4. Epub ahead of print. 120. Lloyd JC, Banez LL, Aronson WJ, Terris MD, Presti JC Jr., Amling CL, Kane CJ, Freedland SJ. Preoperative predictors of blood loss at the time of radical prostatectomy: results from the SEARCH database. Prostate Cancer Prostatic Dis. Mar 2009. Epub ahead of print. 121. Banez LL, Terris MK, Aranson WJ, Presti JC Jr, Kane CJ, Amling CL, Freedland SJ. Race and time from diagnosis to radical prostatectomy: does equal access mean equal timely access to the operating room? Cancer Epidemiology Biomarkers Prev. 18(4); 1208-12, Apr 2009. 122. Amling CL. Quality of life and satisfaction with prostate cancer treatment. Curr Urol Rep.10(3):161-2, May 2009. 123 Colli JL, Amling CL. Chemoprevention of prostate cancer: what can be recommended to patients? Curr Urol Rep 10(3):165-71, May 2009. 17

124. Moreira DM, Jayachandran J, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Stephenson AJ, Freedland SJ. Validation of a nomogram to predict disease progression following salvage radiotherapy after radical prostatectomy: results from the SEARCH database. BJU Int. May 2009. Epub ahead of print. 125. Moreira DM, Banez LL, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. Predictors of secondary treatment following biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. BJU June 2009. Epub ahead of print. 126. Banez LL, Sun L, Trock BJ, Han M, Partin AW, Aronson WJ, Terris MK, Presti JC Jr, Kane CJ, Amling CL, Moul J, Freedland SJ. Body mass index and prostatic specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy. J Urol June 2009. Epub ahead of print. 127. Teeter AE, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. Does early prostate specific antigen doubling time (ePSADT) after radical prostatectomy, calculated using PSA values from the first detectable until the first recurrence value, correlate with standard PSADT? A report from the Shared Equal Access Regional Cancer Hospital Database Group. BJU Int June 2009. Epub ahead of print. 128. Amling CL. Early results of the selenium and vitamin E prostate cancer prevention study. Curr Urol Rep.10(4):242-3, July 2009.

INVITED PUBLICATIONS AND BOOK CHAPTERS 1. Lerner, S.E., Amling, C.L., Kaynan, A.M., Blute, M.L. and Zincke, H.: The role of salvage surgery in radio-recurrent/resistant carcinoma of the prostate. AUA Update, Vol 28 (Lesson 8), 1999. 2. Riffenburgh RH, Amling CL: Use of early PSA velocity to predict eventual abnormal values in men at risk for prostate cancer. Am J Urol Rev 1(6):256-262, 2003. 3. Amling CL: Use of a Competency-Based Computerized Resident Evaluation System for Urology Training Programs, AUA News, Vol 9, Issue 2, 2004. 4. Ward JW, Amling CL, McKusick MA: The use of percutaneous transcatheter embolization in urology. AUA Update, Vol 22 (Lesson 39 ), 2003. 5. Amling CL:  How the addition of hormones improves outcome: Hormone therapy and surgery.  Eur  Urol Supplements 3(1):27­31, 2004. 6. Amling CL:  Letter of Response – Reaction to Body Mass Index, Family Urology, Vol 9, Issue 2,  Summer 2004. 7. Amling CL:  Commentary on Does Obesity Affect Outcome in Prostate Cancer. Am J Urol Rev 2(7):323-325, 2004 8. Amling CL. Hormonal therapy: orchiectomy. In: Bostwick D, Crawford D, Higano C, Roach M, eds. Prostate Cancer Book. American Cancer Society; Fall 2004 (In press) 9. Amling CL. Surgery: questions to ask your medical team about surgery. In: Bostwick D, Crawford D, Higano C, Roach M, eds. Prostate Cancer Book. American Cancer Society; Fall 2004 10. Amling CL. Definition of failure recurrence after primary therapy – radical prostatectomy. In: Vogelzang NJ, Shipley WU, Scardino PT, Coffey DS, eds. Comprehensive Textbook of Genitourinary Oncology, 3rd Edition. Philadelphia, PA; Lippincott, Williams & Wilkins 11. Amling CL. Relationship Between Obesity and Prostate and Renal Cancer – Journal of Alternative and Complementary Medicine 12. Amling CL. Evidence­Based Use of Neoadjuvant and Adjuvant Hormonal Therapy with  Radiotherapy and Radical Prostatectomy. AUA Postgraduate Course Handout, May 2005. 18

13. Amling CL. Biochemical Recurrence after Localized Treatment, Urologic Clinics of North America,  Vol 33, No 2, 2006. 14. Amling CL.  Prostate­specific Antigen and Detection of Prostate Cancer:  What Have We Learned  about What Should We Recommend for Screening?  In: Current Treatment Options in Oncology,  7:337­345, Philadelphia (PA), Current Science, 2006. 15. Amling CL and Clayton DB.  Urologic Principles for the General Surgeon. In: General Surgery:  Principles and International Practice, Northport (NY), Springer (In press). 16. Amling CL, section editor. Prostate Cancer. In: Current Prostate Reports, Vol 6, No 1, Philadelphia (PA): Current Medicine, February 2008.

PUBLISHED ABSTRACTS 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11.

12. 13. 14. 15.

Amling, C.L., Kinney, R.D., Dodge, R.K. and Robertson, C.N.: Image analysis of DNA ploidy and cell proliferation in prostate cancer: correlation to tumor volume, Invasiveness and Gleason grade. J Urol 149 (supplement): 394A, 1993. Amling, C.L., Perez, L.M., Russell, L.C., Seigler, H.F. and Weinerth, J.L.: Primary genitourinary melanoma: Review of 37 cases. J Urol 149 (supplement): 497A, 1993. Amling, C.L., Kerns, B.M., Tello, J.W., Layfield, L.J. and Robertson, C.N.: Image analysis of DNA ploidy on touch imprint specimens from small core needle biopsies of the prostate. J Urol 149 (supplement): 394A, 1993. Perez, L.M., Amling C.L., Thrasher, J.B., Newman, G.E., Joyner, R.E. and Anderson, E.E.: Palliative urinary diversion for ureteral obstruction as a consequence of metastatic prostate cancer. J Urol 149 (supplement): 429A, 1993. Amling, C.L., Thrasher, J.B., Frazier, H.A., Robertson, J.E., Vollmer, R.T. and Paulson, D.F.: Radical cystectomy for squamous cell carcinoma of the bladder. J Urol 151 (supplement): 451A, 1994. Amling C.L., Thrasher, J.B., Frazier, H.A. and Paulson, D.F.: Radical cystoprostatectomy for transitional cell carcinoma of the prostate. J Urol 153 (supplement): 393A, 1995. Amling, C.L., O’Hara, S.M., Wiener, J.S. and King, L.R.: Renal ultrasound changes following pyeloplasty in children with UPJ obstruction: Long term outcome in 47 renal units. Pediatrics, October 1995. Amling, C.L., Bergstralh, E.J., Blute, M.L. and Zincke, H.: Charlson comorbidity score and clinical Gleason grade predict long-term survival in patients with prostate cancer undergoing radical prostatectomy. J Urol 157 (supplement): 796, 1997. Blute, M.L., Amling, C.L., Bergstralh, E.J., Zincke, H. and Bostwick, D.G.: Impact of site-specific positive margins in organ-confined prostate cancer. J Urol 157 (supplement): 805, 1997. Amling, C.L., Martin, S.K., Blute, M.L. and Zincke, H.: Contemporary morbidity of radical retropubic prostatectomy for localized prostate cancer. J Urol 157 (supplement): 989, 1997. Amling, C.L., Elliott, D.S., Slezak, J.M., Blute, M.L. and Zincke, H.: Should patients with very high serum PSA levels (≥ 50 ng/ml) undergo radical prostatectomy? J Urol 157 (supplement): 1247, 1997. Amling, C.L., Bergstralh, E.J., Martin, S.K., Slezak, J.K., Blute, M.L. and Zincke, H: Longterm outcome following preoperative androgen deprivation therapy for clincal stage T3 prostate cancer. J Urol 157 (supplement): 1297, 1997. Amling, C.L., Martin, S.K., Slezak, J.K., Blute, M.L. and Zincke, H.: Salvage prostatectomy for radiation refractory prostate cancer. J Urol 159 (supplement): 1296, 1998. Amling, C.L., Bergstralh, E.J., Blute, M.L. and Zincke, H.: Factors predicting outcome following radical prostatectomy for DNA aneuploid prostate cancer. J Urol 159 (supplement): 492, 1998. Amling, C.L., Bergstralh, E.J., Blute, M.L. and Zincke, H.: Prostate cancer progression rates 19

16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31.

32.

following radical prostatectomy for patients with seminal vesicle involvement. J Urol 159 (supplement): 493, 1998. Blute, M.L., Amling, C.L., Bryant, S.C. and Zincke, H.: Management and outcome of bilateral synchronous solid renal neoplasms. J Urol 159 (supplement): 565, 1998. Kane, C.J., Amling, C.L., Johnstone, P.A., Pak, N., Foley, J.P. and Moul, J.W.: Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. J Urol 161 (supplement): 677, 1999. Tarman, G.J., Kane, C.J., Moul, J.W., Thrasher, J.B., Foley, J.P., Riffenburgh, R.H. and Amling, C.L.: The impact of socioeconomic status on clinical parameters of radical prostatectomy patients in an equal access healthcare system. J Urol 161 (supplement): 1272, 1999. Amling, C.L., Kane, C.J., Ward, J.F., Roberts, J.L., Lance, R.S., Friedrichs, P.A. and Moul, J.W.: The impact of obesity on pathologic variables and surgical complications in patients nndergoing radical prostatectomy for clinically localized prostate cancer. J Urol 163 (supplement): 254, 2000. Amling, C.L., Blute, M.L., Bergstralh, E.J., Slezak, J. and Zincke, H.: Long-term hazard of progression after radical prostatectomy in patients with clinically localized prostate cancer: Continued risk of biochemical failure after five years. J Urol 163 (supplement): 1496, 2000. Amling, C.L., Blute, M.L., Bergstralh, E.J., Slezak, J. and Zincke, H.: Defining biochemical progression after radical prostatectomy: What is the most appropriate PSA cut-point? J Urol 163 (supplement): 1264, 2000. Borboroglu, P.G., Sands, J.P., Roberts, J.L. and Amling, C.L.: Risk factors for vesicourethral anastomotic stricture after radical prostatectomy. J Urol 163 (supplement): 1288, 2000. Borboroglu, P.G., Groff, W.F., Powell, C.R. and Amling, C.L.: Location of postive sextant biopsy does not correlate with sites of positive surgical margins in radical prostatectomy specimens. J Urol 163 (supplement): 1434, 2000. Ward, J.F., Nowacki, M.R., Sands, J.P. and Amling, C.L.: Malignant cells in prostate washings predicts biochemical progression after radical prostatectomy. J Urol 163 (supplement): 1431, 2000. Knight, M.K., Amling, C.L., Karnes, J., King, B.F., Blute, M.L. and Segura, J.W.: Diagnosis and treatment of prostate cancer in patients after rectal resection. J Urol 163 (supplement): 398, 2000. Borboroglu, P.G., Amling, C.L., Monga, M. and Kane, C.J.: Ureteral stenting after distal ureteroscopy for stones: A prospective randomized study assessing pain, outcomes and complications. J Urol 163 (supplement): 1502, 2000. Borboroglu, P.G., Sur, R.L., Roberts, J.L. and Amling, C.L.: Repeat biopsy strategy in patients with atypical small acinar proliferation (ASAP) or high grade prostatic intraepithelial neoplasia (HGPIN) on initial prostate needle biopsy. J Urol 165 (supplement): 402, 2001. Johnstone, P.A.S., McFarland, J.T., Riffenburgh, R.H. and Amling, C.L.: The efficacy of digital rectal examination in the followup of patients undergoing external beam radiotherapy for prostate cancer. J Urol 165 (supplement): 1336, 2001. Gray, C.L., Sears, S.T., Puckett, M.K., Kane, C.J., Ward, J.F. and Amling, C.L.: Prospective comparison of computed tomography and intravenous pyelography in the initial evaluation of asymptomatic microhematuria. J Urol 165 (supplement): 1604, 2001. Johnstone, P.A., Kane, C., Sun, L., Wu, H., Moul, J. and Amling, C.L.: The effect of ethnicity on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system. Radiology 221 (P): 224-225 (abstract 31), 2001. Sun L, McLeod D, Amling C, Lance R, Kusuda L, Donahue T, Foley J, Hui N, Sexton W, Soderdahl D, Skaare VK, Moul J: Epidemiology of prostate cancer, its treatment and outcome: Introduction of the Department of Defense Center for Prostate Disease Research (DOD-CPDR) multicenter prostate cancer database with 307,931 records on 13,878 men. Eur Urol Supplements 1(1):74, 2002. Moul, J.W., McLeod, D.G., Amling, C.L., Lance, R., et al: Assessment of biochemical disease free survival (DFS) in patients with hormonal therapy (HT) started for PSA-only recurrence 20

33. 34. 35. 36. 37. 38. 39.

40.

41. 42. 43.

44. 45. 46. 47.

48.

following radical prostatectomy. J Urol 167 (supplement): 699, 2002. Sun, L., McLeod, D.G., Amling, C.L., Lance, R., et al: Who likely receives hormonal therapy (HT) after PSA-only recurrence following radical prostatectomy? A retrospective analysis on 3790 cases from DOD CPDR National Database. J Urol 167 (supplement): 1194, 2002. Amling, C.L. and Riffenburgh, R.H.: The use or early PSA velocity to predict eventual development of abnormal PSA values: Potential use in the early identification of men at risk for prostate cancer. J Urol 167 (supplement): 1288, 2002. Sur, R.L., Borboroglu, P.G., Roberts, J.L. and Amling, C.L.: A randomized prospective comparison of extensive transrectal prostate biopsy to standard biopsy for the diagnosis of prostate cancer. J Urol 167 (supplement): 1317, 2002. Smith, L.J., Hollis-Perry, K.M., Redden, T., Mondragon, R.M., Amling, C.L.: Does extensive prostate biopsy more accurately predict cancer grade, stage and margin status at the time of radical prostatectomy? J Urol 167 (supplement): 1322, 2002. Freedland SJ, Presti JC, Terris MK, Kane CJ, Aronson WJ, Dorey F, Amling CL: Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: Results from the SEARCH database. J Urol 169 (supplement) 295, 2003. Freedland SJ, Presti JC, Terris MK, Aronson WJ, Kane CJ, Elashoff DA, Amling CL: Should a positive surgical margin following radical prostatectomy be pathological stage T2 or T3?: Results from the SEARCH database. J Urol 169 (supplement) 300, 2003. Sun L, Moul JW, Wu H, McLeod DG, Amling CL, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Donahue T, Xao M, Chang J: Natural history of prostate cancer in 3605 CPDR patients receiving radical prostatectomy and factors affecting post-treatment clinical metastatsis in the PSA era. J Urol 169 (supplement) 398, 2003. Wu H, Sun L, Moul JW, Wu H, McLeod DG, Amling CL, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Donahue T, Banez L: An algorithm with preoperative variables to predict PSA recurrence in prostate cancer patients receiving radical prostatectomy. J Urol 169 (supplement) 399, 2003. Crain DS, Roberts JL, Amling CL: Practice patterns in vasectomy reversal: Results of a questionnaire study among practicing urologists. J Urol (supplement) 409, 2003. Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, Presti JC: Percent of biopsy cores with cancer is a significant independent predictor of PSA failure after radical prostatectomy: Results from the SEARCH database. J Urol 169 (supplement) 444, 2003. Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling CL, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Donahue T: Pretreatment total testosterone level predicts pathologic stage among radical prostatectomy patients with localized prostate cancer. J Urol 169 (supplement) 456, 2003. Wu H, Sun L, Moul JW, Wu H, McLeod DG, Amling CL, Lance R, Kusuda L, Donahue T, Foley J, Chung A, Sexton W, Soderdahl D: Watchful waiting and predicting factors for secondary treatment in prostate cancer. J Urol 169 (supplement) 493, 2003. Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr., Amling CL, Elashoff D, and Terris MK. Obesity is an independent predictor of biochemical failure following radical prostatectomy. J Urol 171 (supplement) 115, 2004. Amling CL, Spencer CR, Roberts JL: Practice patterns in transrectal ultrasound guided prostate biopsy: Results of a questionnaire survey of practicing urologists. J Urol 171 (supplement) 478, 2004. Wu H, Moul JW, Sun L, McLeod DG, Amling CL, Donahue TF, Kusuda L, Sexton WJ, O’Reilly KJ, Hernandez J, Chung A, Smith K. Prostate cancer mortality after radical prostatectomy or radiation therapy in men with clinically localized prostate cancer. J Urol 171 (supplement) 118, 2004. Chen Y, Moul JW, Sun L, McLeod DG, Amling CL, Donahue TF, Kusuda L, Sexton WJ, O’Reilly KJ, Hernandez J, Chung A, Smith K. Comtemporary experience with hormone refractory prostate 21

49. 50. 51.

52. 53. 54. 55.

56. 57. 58. 59. 60. 61. 62. 63.

64.

cancer (HRPC-Stage D3) in the PSA era: Report from the DOD CPDR national database. J Urol 171 (supplement) 118, 2004. Freedland SJ, Kane CJ, Presti JC Jr., Terris MK, Aronson WJ, and Amling CL. Do younger men have better biochemical outcomes following radical prostatectomy? J Urol 171 (supplement) 272, 2004. Chung A, Sun L, Carter CA, Moul JW, Zhao X, McLeod DG, Amling CL, Donahue TF, Kusuda L, Sexton WJ, O’Reilly KJ, Hernandez J, Smith K. Changing face of prostate cancer in the PSA era: Results from the CPDR national database. J Urol 171 (supplement) 125, 2004. Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, Sexton WJ, Soderdahl DW, DonahueTF, Foley JP, Chung AK, McLeod DG: Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Urol 171 (supplement) 116, 2004. Sexton WJ, McDonough RC, Hernandez J, Sun L, Moul JW, Amling CL, Donahue TF, Kusuda L, O’Reilly KJ, Chung A, Smith K. Prostate cancer in men less than or equal to 40 years of age during the PSA era. J Urol 171 (supplement) 126, 2004. Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Presti JC Jr. , Trock B, and Amling CL. Men with normal pre-operative serum PSA values have better biochemical outcomes following radical prostatectomy. J Urol 171 (supplement) 332, 2004. Amling CL, Williams SR, Lance R, McLeod DG, Kusuda L, Donahue T, Foley J, Sexton W, Soderdahl DW, Sun L, Moul JW: Does obesity increase intraoperative and postoperative complications in men undergoing radical prostatectomy? J Urol 171 (supplement) 215, 2004. Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, and Presti JC Jr. Percent of prostate needle biopsy cores with cancer from the most involved side of the biopsy is a better predictor of PSA recurrence following radical prostatectomy than the total percent of cores with cancer. J Urol 171 (supplement) 274, 2004. Amling CL, Sun L, Moul JW, Chen Y, McLeod DG, Donahue TF, Kusuda L, Sexton WJ, O’Reilly KJ, Hernandez J, Chung A, Smith K. Pre and post-surgery factors affecting the outcomes of patients with intermediate risk prostate cancer. J Urol 171 (supplement) 277, 2004. Moul JW, Sun L, Amling CL, Fia Y, Chen Y, McLeod DG, Donahue TF, Kusuda L, Sexton WJ, O’Reilly KJ, Hernandez J, Chung A, Smith K. How long can radical prostatectomy (RP) safely be delayed? CPDR experience from 3324 cases. J Urol 171 (supplement) 312, 2004. Langenstroer P, Poulton T, Kramer B, Cutting B, Amling CL, Lance RS, Thrasher JB. Multiinstitutional evaluation of depo-provera for the treatment of hot flashes associated with androgen ablation for prostate cancer. J Urol 171 (supplement) 384, 2004. Altamar HO, Kolkow, S, Amling CL: Incidental genitourinary abnormalities detected by CT colonography in a large colorectal cancer screening population. J Urol 173 (supplement) 384, 2005. Sarvis J, Crain D, Williams S, Amling CL: Randomized prospective comparison of IV conscious sedation and lidocaine block for prostate biopsy. J Urol 173 (supplement) 384, 2005. Freedland SJ, Isaacs WB, Platz E, Terris M, Aronson WJ, Amling CL, Presti JC Jr. , and Kane CJ. Prostate size and risk of high-grade, advanced cancer, and biochemical progression following radical prostatectomy. J Urol 173 (supplement) 384, 2005. Shah SR, Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr, Amling CL, and Terris MK: Agent Orange exposure and Risk of Advanced Disease and Biochemical Progression after Radical Prostatectomy: Results from the SEARCH Database. J Urol 175 (supplement) 42, 2006. Bastian PJ, Gonzalgo ML, Mangold LA, Aronson WJ, Terris MK, Kane CJ, Amling CL, Presti JC Jr., Epstein JI, Partin AW, and Freedland SJ: Pathological and Biochemical Outcomes after Radical Prostatectomy for Men with a Biopsy Gleason Score of 8 to 10. J Urol 175 (supplement) 215, 2006. Scales CD Jr., Amling CL, Kane CJ, Presti JC Jr., Terris MK, Aronson WJ, and Freedland SJ: Can Unilateral Prostate Cancer be Reliability Predicted based upon Biopsy Features? J Urol 175 22

65. 66.

67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81.

(supplement) 373, 2006. Freedland SJ, Platz EA, Presti JC Jr, Aronson WJ, Amling CL, Kane CJ, and Terris MK: Obesity, Serum PSA, and Prostate Size: Implications for Prostate Cancer. J Urol 175 (supplement) 487, 2006. Cooperberg MR, Freedland SJ, Pasta DJ, Elkin EP, Presti JC Jr, Amling CL, Terris MK, Aronson WJ, Kane CJ, and Carroll PR: Multi-institutional validation of the UCSF Cancer of the Prostate Risk Assessment (CAPRA) for prediction of recurrence following radical prostatectomy. J Urol 175 (supplement) 531, 2006. Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Terris MK, and Presti JC Jr.: Upgrading and Downgrading of Prostate Needle Biopsies: Risk Factors and Clinical Implications. J Urol 175 (supplement) 534, 2006. Nelles JL, Freedland SJ, Presti JC Jr., Terris MK, Aronson WJ, Amling CL, and Kane CJ: Nerve Sparing Does Not Increase the Risk of Biochemical Recurrence Results From the SEARCH Database. J Urol 177 (supplement) 6, 2007. Heath EI, Kattan MW, Powell IJ, Sakr W, Brand TC, Rybicki B, Thompson IM, Aronson WJ, Terris MK, Kane CJ, Presti JC Jr., Amling CL, and Freedland SL: Are the Partin Tables Accurate for Africian-American Men in the United States? J Urol 177 (supplement) 111, 2007. King CR, Freedland SJ, Terris MK, Aronson WJ, Kane CJ, Amling CL, and Presti JC Jr.: The Optimal Timing, Cutoff and Method of Calculation of Preoperative PSA Velocity to Predict Relapse After Prostatectomy: A Report from SEARCH. J Urol 177 (supplement) 128, 2007. Hamilton RJ, Amling CL, Kane CJ, Aronson WJ, Terris MK, Presti JC Jr., and Freedland SJ: African American Race, Risk of Biochemical Recurrence, and PSADT after Radical Prostatectomy. J Urol 177 (supplement) 131, 2007. Shah SR, Freedland SJ, Kane CJ, Aronson WJ, Presti JC Jr., Amling CL, and Terris MK: Agent Orange Exposure Among Black Men is a Stronger Predictor of PSA Recurrence and Rapid Postrecurrence PSADT Than Among White Men. J Urol 177 (supplement) 153, 2007. Freedland SJ, Hamilton RJ, Aronson WJ, Terris MK, Presti JC Jr., Amling CL, and Kane CJ: Obesity, Risk of Biochemical Recurrence, and PSADT After Radical Prostatectomy. J Urol 177 (supplement) 154, 2007. Hamilton RJ, Buschemeyer WC III, Terris MK, Aronson WJ, Kane CJ, Presti JC Jr., Amling CL, and Freedland SJ: Significance of the Apical Margin in Radical Prostatectomy: Results from the SEARCH Database. J Urol 177 (supplement) 159, 2007. Buschemeyer WC III, Hamilton RJ, Amling CL, Kane CJ, Terris MK, Aronson WJ, Presti JC Jr., and Freedland SJ: Is a Positive Bladder Neck Margin Truly a T4 Lesion in the PSA Era? J Urol 177 (supplement) 282, 2007. Clayton DB, Colli JL, Seale JR, Stewart AF, Lin HY, and Amling CL: The Kinetics of Prostate Specific Antigen Decline as a Predictor of Outcomes in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer. J Urol 177 (supplement) 337, 2007. Banez LL, Hamilton RJ, Vollmer RT, Moul JW, Amling CL, Kane CJ, Aronson WJ, Terris MK, Presti JC Jr., and Freedland SJ: Can Hemodilution Explain the Lower PSA Concentrations Among Obese Men? J Urol 177 (supplement) 468, 2007. Strang AM, Lockhart ME, Kenney PJ, Amling CL, Urban DA, El-Galley R, Burns JR, Colli JL, Hammontree LN and Kolettis PN: Computed Tomographic Angiography for Renal Donor Evaluation Leads to Higher Exclusion Rate. J Urol 177 (supplement) 565, 2007. Strang AM, Lockhart ME, Burns JR, Amling CL, and Kolettis PN: Short Term Outcomes of Living Donor Allograft Nephrolithiasis in Renal Transplant Donors and Recipients. J Urol 177 (supplement) 594, 2007. Scales CD, Terris MK, Aronson WJ, Presti JC, Kane CJ, Amling CL, Krupski TL, and Freedland SJ: Does Practice Reflect the Evidence? Lymph Node Dissection with Radical Prostatectomy: Results from the SEARCH Database. J Urol 179 (supplement) 3, 2008. Turley RS, Hamilton RJ, Terris MK, Kane CJ, Aronson WJ, Presti JC, Amling CL, and Freedland 23

82.

83. 84. 85. 86.

87.

88.

89. 90. 91.

92. 93.

94. 95.

SJ: Small TRUS Volume Predicts Clinically Significant Gleason Score Upgrading After Radical Prostatectomy: Results from the SEARCH Database. J Urol 179 (supplement) 51, 2008. Teeter AE, Aronson WJ, Presti JC, Terris MK, Amling CL, Kane CJ, and Freedland SJ: Does Early PSADT, Calculated Starting at the First Detectable PSA After Radical Prostatectomy (RP), Correlate with Standard PSADT? A Report from the SEARC Database Group. J Urol 179 (supplement) 65, 2008. Banez LL, Hamilton RJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, and Freedland SJ: Higher Cholesterol Increases the Risk of Biochemical Failure After Radical Prostatectomy: Results from the SEARCH Database Group. J Urol 179 (supplement) 68, 2008. Teeter AE, Banez LL, Aronson WJ, Presti JC, Terris MK, Amling CL, Kane CJ, and Freedland SJ: What Are the Factors Associated with a Short PSA Doubling Time? A Report from the SEARCH Database Group. J Urol 179 (supplement) 149, 2008. Lin DW, Terris MK, Aronson WJ, Presti JC, Kane CJ, Amling CL, and Freedland SJ: Outcome Among Men with Patholigical Gleason SUM 8-10 Prostate Cancer at the Time of Radical Prostatectomy: Results from the SEARCH Database. J Urol 179 (supplement) 151, 2008. Jayachandran J, Banez LL, Levy DE, Aronson WJ, Terris MK, Presti JC, Amling CL, Kane CJ, and Freedland SJ: Risk Stratification Among Men with Positive Surgical Margins or Extracapsular Disease After Radical Prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. J Urol 179 (supplement) 251, 2008. Kane CJ, Neville TB, Kaminski DA, Falvello VB, Terris MK, Aronson WJ, Presti JC, Amling CL, and Freedland SJ: PSA Velocity (PSAV) to Cancer-Specific PSA (PSA(PCA)) Ratio Increases with Higher Gleason Score: Results from the SEARCH Database. J Urol 179 (supplement) 601, 2008. Jayachandran J, Banez LL, Aronson WJ, Terris MK, Presti JC, Amling CL, Kane CJ, Sun L, Moul JW, and Freedland SJ: Obesity as a Predictor of Adverse Outcome Across Black and White Race: Results from the SEARCH and Duke Prostate Center Databases. J Urol 179 (supplement) 647, 2008. Kane CJ, Terris MK, Aronson WJ, Presti JC, Amling CL, and Freedland SJ: Outcomes After Radical Prostatectomy Among Men Who Are Candidates for Active Surveillance: Results from the SEARCH Database. J Urol 179 (supplement) 651, 2008. Klink JC, Banez LL, Powell IJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, and Freedland SJ: T1C Disease in Black Men: A More Aggressive Disease? Results from the SEARCH Database. J Urol 179 (supplement) 652, 2008. Freedland SJ, Terris MK, Aronson WJ, Presti JC, Amling CL, and Kane CJ: Over the Last 15+ Years, the Percentage of Men Undergoing Radical Prostatectomy Who Are Candidates for Active Surveillance Has Not Changed: Results From the SEARCH Database. J Urol 179 (supplement) 653, 2008. Colli JL, Stands C, Martin B, and Amling CL: Urologist Population Density and PSA Screening Practices Predict Prostate Cancer Mortality Rates in the United States. J Urol 179 (supplement) 687, 2008. Freedland SJ, Moul JW, Sun L, Neville TB, Kaminski DA, Falvello VB, Terris MK, Aronson WJ, Presti JC, Amling CL, and Kane CJ: Dynamic Screening Detects Prostate Cancer (PC) Earlier and Would Lead to Improved Cancer Control: Results from the Duke Prostate Center and the SEARCH Database. J Urol 179 (supplement) 688, 2008. Clayton DB, Spencer CL, and Amling CL: Practice Patterns of Transrectal Ultrasound Guided Prostate Biopsy: Results of a Questionaire Survey of Practicing Urologists. J Urol 179 (supplement) 712, 2008. Banez LL, Sun L, Aronson WJ, Terris MK, Presti JC, Amling CL, Kane CJ, Moul JW, and Freedland SJ: Is PSA a Poor Predictor of Adverse Pathology and Biochemical Failure Following Radical Prostatectomy in Obese Men? J Urol 179 (supplement) 722, 2008. 24